Canada markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.72+0.46 (+2.39%)
At close: 04:00PM EST
19.33 -0.39 (-1.98%)
After hours: 04:05PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close19.26
Open19.26
Bid19.49 x 800
Ask19.52 x 1000
Day's Range19.11 - 19.81
52 Week Range13.92 - 28.18
Volume636,423
Avg. Volume762,826
Market Cap1.598B
Beta (5Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

    Myriad Genetics continues to advance non-invasive prenatal screening with Prequel® and the forthcoming FirstGene™ test using AMPLIFY™ technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a recent guideline update by the American College of Medical Genetics and Genomics (ACMG), reaffirming the clinical value of non-invasive prenatal screening (NIPS) for a range of chr

  • GlobeNewswire

    Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

    SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be available through a live webcast on the Myriad Genetics Investor Relations website. An archive

  • GlobeNewswire

    Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

    New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of five senior executives to help further strengthen the company’s product roadmap and improve commercial execution. Marc Leighton recently joined Myriad as Senior Vice President (SVP) for Product Management. Lei